

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number  
**WO 2005/080430 A2**

(51) International Patent Classification<sup>7</sup>: **C07K 16/00**

(21) International Application Number:  
PCT/IB2005/000305

(22) International Filing Date: 8 February 2005 (08.02.2005)

(25) Filing Language: Italian

(26) Publication Language: English

(30) Priority Data:  
MI2004A000251 16 February 2004 (16.02.2004) IT

(71) Applicants (for all designated States except US): **UNIVERSITA' DEGLI STUDI DI ROMA "TOR VERGATA"** [IT/IT]; Via Orazio Raimondo, 18, I-00173 Roma (IT). **ISTITUTI FISIOTERAPICI OSPITALIERI** [IT/IT]; Via Elio Chinesi 53, I-00128 Roma (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NOVELLI, Giuseppe** [IT/IT]; Via Silia Italico 89/D, I-00040

Monteporzio Catone (IT). **SPAGNOLI, Luigi, Giusto** [IT/IT]; Via Bigelli 47, I-00017 Nerola (IT). **PUCCI, Sabina** [IT/IT]; Via Vinicio Cortese 180, I-00128 Roma (IT). **CONTINO, Gianmarco** [IT/IT]; Via Fonteiana 126, I-00126 Roma (IT). **CITRO, Gennaro** [IT/IT]; Via Fermo 7, I-00182 Roma (IT).


(74) Agent: **MARGUTTI, Roberto**; Bugnion S.p.A., Viale Lancetti, 17, I-20158 Milano (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: ANTI-UBE4A/UFD2B POLYCLONAL ANTIBODY AND ITS USE THEREOF AS DIAGNOSTIC AND PROGNOSTIC MARKER OF 11Q23 REGION ALTERATIONS

(57) Abstract: The subject of this invention is an anti-UBE4A/Ufd2b polyclonal antibody. Moreover, this invention refers to the use of said antibody as a diagnostic and prognostic marker of alterations in the 11q23 region.





(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*